ChemoMetec AS (OCSE:CHEMM) ROCE %: 36.54% (As of Dec. 2025)


OCSE:CHEMM ChemoMetec AS OCSE:CHEMM
99 GF Score
Price kr369.20
GF Value kr523.33
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is ChemoMetec AS ROCE %?

ChemoMetec AS OCSE:CHEMM +0.76% 99 ROCE % is 36.54% as of Dec. 2025. GuruFocus rates OCSE:CHEMM with a GF Score™ of 99/100 and a GF Value™ of kr523.33 (Modestly Undervalued). The stock has 2 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. ChemoMetec AS's annualized ROCE % for the quarter that ended in Dec. 2025 was 36.54%.

ChemoMetec AS  (OCSE:CHEMM) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

ChemoMetec AS ROCE % Related Terms

ChemoMetec AS ROCE % Historical Data

* Premium members only.

The historical data trend for ChemoMetec AS's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ChemoMetec AS ROCE % Chart

ChemoMetec AS Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 46.54 64.29 51.28 31.65 38.21

ChemoMetec AS Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 34.84 31.79 44.93 33.34 36.54
OCSE:CHEMM
99GF Score
ChemoMetec AS OCSE:CHEMM
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ChemoMetec AS ROCE % Calculation

ChemoMetec AS's annualized ROCE % for the fiscal year that ended in Jun. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Jun. 2025 )  (A: Jun. 2024 )(A: Jun. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Jun. 2025 )  (A: Jun. 2024 )(A: Jun. 2025 )
=240.571/( ( (676.673 - 98.529) + (828.046 - 146.992) )/ 2 )
=240.571/( (578.144+681.054)/ 2 )
=240.571/629.599
=38.21 %

ChemoMetec AS's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=245.058/( ( (828.046 - 146.992) + (783.37 - 123.279) )/ 2 )
=245.058/( ( 681.054 + 660.091 )/ 2 )
=245.058/670.5725
=36.54 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 36.54% mean?
ChemoMetec AS (OCSE:CHEMM) has a ROCE % of 36.54% as of Dec. 2025.
Is ChemoMetec AS's ROCE % too high?
ChemoMetec AS's current ROCE % is 36.54%. The Medical Devices & Instruments industry median ROCE % is 2.23. ChemoMetec AS's value of 36.54% is 1538.6% above this industry median. Overall, ChemoMetec AS has a GF Score™ of 99/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ChemoMetec AS's ROCE % compare to ABT and SYK?
ChemoMetec AS's ROCE % of 36.54% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROCE % is 2.23. ChemoMetec AS's value of 36.54% is 1538.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Medical Devices & Instruments company?
The median ROCE % among Medical Devices & Instruments companies is 2.23, based on 814 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ChemoMetec AS's current ROCE % of 36.54% is 1538.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median ROCE % is 2.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ChemoMetec AS's current ROCE % is 36.54%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ChemoMetec AS stock overvalued right now?
Based on GuruFocus' analysis, ChemoMetec AS (OCSE:CHEMM) is currently considered Modestly Undervalued. The stock's GF Value™ is kr523.33, compared to a current price of kr369.20 — trading 29.5% below its estimated fair value. The current ROCE % is 36.54% and 1538.6% above the Medical Devices & Instruments industry median of 2.23. ChemoMetec AS's overall GF Score™ is 99/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For ChemoMetec AS (OCSE:CHEMM), the current ROCE % is 36.54% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ChemoMetec AS (OCSE:CHEMM) Overvalued in 2026?

Based on GuruFocus' analysis, ChemoMetec AS stock appears to be undervalued. The current stock price of kr369.20 is trading 29.5% below its estimated GF Value™ of kr523.33. GuruFocus considers ChemoMetec AS to be Modestly Undervalued.

Key valuation signals for OCSE:CHEMM:

  • ROCE %: 36.54%
  • GF Value™: kr523.33 vs. price of kr369.20 (29.5% below fair value)
  • GF Score™: 99/100 with 2 warning signs
  • Industry Position: 1538.6% above the Medical Devices & Instruments median

No single metric tells the full story. See the OCSE:CHEMM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ChemoMetec AS Business Description

Other Exchanges CHEMMc:UK0DZ0:UKCHY:Germany
Address Gydevang 43, Allerod, DNK, 3450
ChemoMetec AS specializes in designing, developing, and producing instruments using patented technology in cell counting and evaluation. It is engaged in the manufacturing and marketing of analytical instruments used for quantitative analysis of cells in liquids. Its applications include Cell Analysis and counting of Mammalian Cells, Yeast Cells, and Sperm Cells. It provides platforms for the determination of viability and cell count of yeast, veterinary semen, mammalian cells, and somatic cells as well as image analysis. It has four segments instruments; consumables; services and others, and the majority of its revenue is generated from the Consumable segment.
99GF Score

Get the complete analysis for OCSE:CHEMM

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr369.20
Price
kr523.33
GF Value